Apollo Hospitals Enterprise growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+15.8%+14.3%+14.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+24.7%+26.4%+16.6%
+27.8%+32.9%+18.8%
+33.1%+61.0%+10.7%
+34.3%+60.9%+9.7%
+7.5%+23.3%+16.1%
+15.3%+18.2%+12.1%
+33.7%+11.3%+39.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

APOLLOHOSP₹8,200.00

Apollo Hospitals Enterprise Ltd.

· Pharma & Health
₹ CrorePeersFORTISMAXHEALTHMEDANTASUNPHARMACIPLADRREDDYDIVISLABTORNTPHARMMcap ₹1.18L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+14.7+14.3+15.8—
EBITDA Growth—+16.6+26.4+24.7—
EBIT Growth—+18.8+32.9+27.8—
Net Income Growth—+10.7+61.0+33.1—
EPS Growth—+9.7+60.9+34.3—
Total Assets Growth—+16.1+23.3+7.5—
Total Equity Growth—+12.1+18.2+15.3—
Cash from Operations Growth—+39.5+11.3+33.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 145%.